Twist Bioscience Corporation— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$104M
↑+16.9% +$15Mvs FY2024 (Q4)
Gross Profit
$54M
↑+26.0% +$11Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $104M | $89M |
| COGS | $50M | $46M |
| Gross Profit | $54M | $43M |
| R&D | $17M | $21M |
| SG&A | $70M | $56M |
| D&A | $6M | $6M |
| Other OpEx | $0 | $0 |
| Operating Income | $0 | $0 |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $0 | $0 |
| Tax | $0 | $0 |
| Net Income | $0 | $0 |
QuarterCharts · SEC EDGAR data · TWST · Comparing FY2025 (Q4) vs FY2024 (Q4)